{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/epilepsy/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"7e16f4d4-24ca-5628-ba07-c486b95e90c5","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 60844df8-cafe-4d08-bc43-205c8d783330 --><h2>Update</h2><!-- end field 60844df8-cafe-4d08-bc43-205c8d783330 -->","summary":null,"htmlStringContent":"<!-- begin item 6ea979d6-ab1c-4dcd-a302-0b501b34d73d --><!-- end item 6ea979d6-ab1c-4dcd-a302-0b501b34d73d -->","topic":{"id":"f8129267-de9a-585d-9e33-8725cd832f5f","topicId":"b393b08f-0928-43ec-abde-ec6b4844fdee","topicName":"Epilepsy","slug":"epilepsy","lastRevised":"Last revised in January 2021","chapters":[{"id":"5b049e7f-5e24-5bcc-af53-ff98c396ad9e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6b88498d-4758-510e-afc3-ed87d1957cad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7a679807-bda2-5ee7-9bde-7ecdc0762be8","slug":"changes","fullItemName":"Changes"},{"id":"7e16f4d4-24ca-5628-ba07-c486b95e90c5","slug":"update","fullItemName":"Update"}]},{"id":"535dff27-4aaa-57fa-80a1-d274bd3b4e59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"48265493-8622-58e8-a018-48a3e42f1148","slug":"goals","fullItemName":"Goals"},{"id":"6c194eb8-ba43-5a68-a78f-51161a41e8db","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c76ab727-494d-527d-a154-b8c28b77d8a4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6d0101cf-ff01-5958-a6fb-ebfbd77e76fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d111772f-1391-5d7f-a517-24a28715a449","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30ff44ac-b721-5577-a601-8c4d55fa848d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"59735dcb-eba6-5d18-bea9-06c5d9c7b253","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4966ce92-afe3-59eb-b304-caf674cc78ae","slug":"definition","fullItemName":"Definition"},{"id":"5bbc7943-77eb-54ab-a31a-50a8a32fb58b","slug":"causes","fullItemName":"Causes"},{"id":"2779c8f9-cdfd-5fc5-9a9e-ff78cc795095","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d76a05be-28cf-51f2-9112-94a3089622ef","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"397d1dd0-2884-5fe1-93ec-86f60bb3f9b0","slug":"complications","fullItemName":"Complications"},{"id":"22457087-3e91-5c25-b650-d494bac54036","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"58d6be4c-1ac7-5b65-b78e-bff25e6e76e6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9854a4d4-10b2-54cb-bde8-bd6851a2a8d3","slug":"assessment","fullItemName":"Assessment"},{"id":"e24eacf4-0b1d-5c8e-beb3-8e4373ee4f96","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b45afa2-7eab-5f3c-baa9-bf2274759bb7","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac1322eb-1276-5dd0-bc64-f83fe4b15961","slug":"suspected-epilepsy","fullItemName":"Scenario: Suspected epilepsy"},{"id":"e72ec2fc-c602-5ac7-9d71-792f49a18f1f","slug":"managing-an-epileptic-seizure","fullItemName":"Scenario: Managing an epileptic seizure"},{"id":"f0726760-8fbd-5900-8525-9c2c98180d5a","slug":"routine-epilepsy-review","fullItemName":"Scenario: Routine epilepsy review"},{"id":"c14abfdb-dd66-5da7-90f4-aed8bb06d929","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"dc732fc8-8397-5b8b-886e-654a3d37dedf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9cc1abe-202c-5ec3-9fa2-4bc1e9003e29","slug":"prescribing-antiepileptic-drugs","fullItemName":"Prescribing antiepileptic drugs"},{"id":"0a33c3f0-2ae8-515f-a2ce-2deeae71dba9","slug":"adverse-effects-of-antiepileptic-drugs","fullItemName":"Adverse effects of antiepileptic drugs"},{"id":"3b7a2ba0-89af-5839-8597-3c9290c9dc23","slug":"enzyme-inducing-antiepileptic-drugs","fullItemName":"Enzyme-inducing antiepileptic drugs"}]},{"id":"b4c758e3-f2ef-5920-8a4b-057ce3f83d8e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"12d642de-145f-5602-a8e5-c6320aab1692","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0cb744d0-8999-57a7-87e5-e25e4df6722a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0ad13cb3-2b8b-56c4-824c-8f777375a7bf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17531a22-0a95-5a68-a007-18cb5384f001","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6b27fc25-7d42-5230-a79b-0c623eb6b606","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7dd141fa-9fe8-54b2-b10c-584815f12e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4b23c7ea-9a6f-5491-aa41-741d7d52e107","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"12e6e1f2-903b-5fcf-a0f5-34f21e543fc4","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field bff31c9f-a446-4753-ad48-6156139d48c4 --><h3>New evidence</h3><!-- end field bff31c9f-a446-4753-ad48-6156139d48c4 -->","summary":null,"htmlStringContent":"<!-- begin item b313995d-20b0-4f33-9370-c1e7e69b7191 --><!-- begin field bceec266-483a-49d6-9f51-b3ec5a016bfe --><h3>Evidence-based guidelines</h3><!-- end field bceec266-483a-49d6-9f51-b3ec5a016bfe --><!-- begin field e8ed6074-6078-4d4b-a788-2102f8cf5845 --><ul><li>NICE (2019) <em>Epilepsies: diagnosis and management.</em> National Institute for Health and Care Excellence. <a href=\"https://www.nice.org.uk/\" data-hyperlink-id=\"da317852-ae4b-46ac-aadb-aaea00baa93d\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/cg137\" data-hyperlink-id=\"fe44109e-11b3-4369-bcdf-aaea00baa95d\">Free Full-text</a>]</li><li>Sen, A., Jette, N., Husain, M. et al. (2020) <em>Epilepsy in older people</em>. Lancet. <a href=\"https://www.thelancet.com/\" data-hyperlink-id=\"c72f0efa-c5fb-4db8-a1ab-ab7300a71346\">www.thelancet.com</a> [<a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33064-8/fulltext\" data-hyperlink-id=\"6bf00005-5845-41ae-a4b1-ab7300a717e4\">Abstract</a>]</li></ul><!-- end field e8ed6074-6078-4d4b-a788-2102f8cf5845 --><!-- begin field 745de867-e3c2-4ca0-b1bc-da45d680c11b --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 745de867-e3c2-4ca0-b1bc-da45d680c11b --><!-- begin field 82983318-088b-4798-b15f-066dc25f19e2 --><p>No new HTAs since 1 April 2019.</p><!-- end field 82983318-088b-4798-b15f-066dc25f19e2 --><!-- begin field 62d52c9d-a338-4af6-8f6d-7e29e7bb52bc --><h3>Economic appraisals</h3><!-- end field 62d52c9d-a338-4af6-8f6d-7e29e7bb52bc --><!-- begin field 148697fc-ca4e-45c7-8e7a-744114bf144c --><p>No new economic appraisals relevant to England since 1 April 2019.</p><!-- end field 148697fc-ca4e-45c7-8e7a-744114bf144c --><!-- begin field 8400a977-a22e-4b8e-8ad0-8c207efa670f --><h3>Systematic reviews and meta-analyses</h3><!-- end field 8400a977-a22e-4b8e-8ad0-8c207efa670f --><!-- begin field 57b7af68-9119-4d5f-ac9a-010c6eebb470 --><ul><li>Panebianco, M., Bresnahan, R., Ramaratnam, R. et al (2020)<em> Lamotrigine add-on therapy for drug-resistant focal epilepsy</em>. Cochrane Systematic Review. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"e1649617-261a-44e3-ac3f-ab8e009243be\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001909.pub3/full\" data-hyperlink-id=\"76683a0c-91c2-4c34-af31-ab8e009244c2\">Free Full-text</a>]</li><li>Maguire, M.J., Jackson, C.F., Marson, A.G. et al (2020) <em>Treatments for the prevention of sudden unexpected death in epilepsy (SUDEP)</em>. Cochrane Systematic Review. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"d13d6ab9-e24b-4b1b-ba9d-ab9200b686b2\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011792.pub3/full\" data-hyperlink-id=\"fe725a1a-0f25-4742-ac9e-ab9200b687b2\">Free Full-text</a>]</li></ul><!-- end field 57b7af68-9119-4d5f-ac9a-010c6eebb470 --><!-- begin field 9d782e06-e098-4898-9b38-badfffa50435 --><h3>Primary evidence</h3><!-- end field 9d782e06-e098-4898-9b38-badfffa50435 --><!-- begin field b28b2a31-c11c-498b-99d8-646c2d3b5e39 --><p>No new primary evidence published since 1 April 2019.</p><!-- end field b28b2a31-c11c-498b-99d8-646c2d3b5e39 --><!-- end item b313995d-20b0-4f33-9370-c1e7e69b7191 -->","subChapters":[]},{"id":"e95a9a0d-09b0-5442-9e01-7f95164b27b4","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 7768e4f1-1675-4e4f-8250-23c602612da9 --><h3>New policies</h3><!-- end field 7768e4f1-1675-4e4f-8250-23c602612da9 -->","summary":null,"htmlStringContent":"<!-- begin item 92442b97-1a21-46b2-b766-6cc8a0777561 --><!-- begin field c6fbf84f-a05e-47bb-8e99-3521f7192375 --><p>No new national policies or guidelines since 1 April 2019.</p><!-- end field c6fbf84f-a05e-47bb-8e99-3521f7192375 --><!-- end item 92442b97-1a21-46b2-b766-6cc8a0777561 -->","subChapters":[]},{"id":"f1d2648e-aed8-5e9e-b0ea-5e80db10d7a8","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 2f69fea5-e3f8-487a-b2ee-df63a3b199a5 --><h3>New safety alerts</h3><!-- end field 2f69fea5-e3f8-487a-b2ee-df63a3b199a5 -->","summary":null,"htmlStringContent":"<!-- begin item 34df5a0a-816f-4b14-8685-dc63a4b038e7 --><!-- begin field 08e588d8-abce-4ae2-a2a8-3f13f598b35e --><ul><li>A review of the risks of major congenital malformations and of adverse neurodevelopmental outcomes for antiepileptic drugs by the Commission on Human Medicines has confirmed that lamotrigine and levetiracetam are the safer of the medicines reviewed during pregnancy. See more <a href=\"https://www.gov.uk/drug-safety-update/antiepileptic-drugs-in-pregnancy-updated-advice-following-comprehensive-safety-review\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"28683a96-68a0-4c44-b964-acaa00fdbfbb\">here</a>.</li></ul><!-- end field 08e588d8-abce-4ae2-a2a8-3f13f598b35e --><!-- end item 34df5a0a-816f-4b14-8685-dc63a4b038e7 -->","subChapters":[]},{"id":"76b3377e-3bb7-5503-8484-947b034f2079","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field efdf6cf6-15a6-47d1-b923-c7a523c7ef9c --><h3>Changes in product availability</h3><!-- end field efdf6cf6-15a6-47d1-b923-c7a523c7ef9c -->","summary":null,"htmlStringContent":"<!-- begin item d19fcefe-ad51-425b-a434-3adb05011707 --><!-- begin field 409eaa9d-12ff-47fb-aea1-14f752a08979 --><p>Cenobamate is a sodium channel blocker, with a binding site different from that of classical sodium channel blockers. The application is based on results from two global randomized controlled trials and an open-label safety study enrolling more than 1,900 adults with uncontrolled focal-onset seizures. For more information, see <a href=\"https://www.biospace.com/article/releases/european-medicines-agency-accepts-arvelle-therapeutics-marketing-authorization-application-for-cenobamate-for-the-adjunctive-treatment-of-focal-onset-seizures-in-adults/\" data-hyperlink-id=\"71ffd9a9-f61c-4836-a006-ab9200b59480\">here</a>.</p><!-- end field 409eaa9d-12ff-47fb-aea1-14f752a08979 --><!-- end item d19fcefe-ad51-425b-a434-3adb05011707 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}